1. Market Research
  2. > Business Services
  3. > Research and Development Market Trends
Drivers for Healthcare R&D Investment in Asia-Pacific : Rise of the APAC R&D Giants

Drivers for Healthcare R&D Investment in Asia-Pacific : Rise of the APAC R&D Giants

  • January 2015
  • 12 pages
  • ID: 2649476
  • Format: PDF


Table of Contents


Investment in Research and Development (R&D) is the key to sustaining innovation and promoting growth in the healthcare industry. This report broadly tracks the events and crucial reasons that have transformed the APAC region into a preferred R&D investment destination. We highlight four countries—China, Singapore, South Korea, and Taiwan—which showed the highest increase in R&D investment between 2009 and 2012. Driven by healthcare market growth in the region, these countries have emerged as hotspots for R&D investment as a result of improved Intellectual Property (IP) regimes, governments’ promotions and incentives, and increased research capabilities.

Executive Summary

For over a decade, investments in R&D have been waning in Western countries and steadily making their way into the APAC region. A large number of companies have set up R&D bases in Asian countries either to specifically cater to the local markets or to develop products that withstand market dynamics in both developed and emerging markets.
Riding the wave of growth in Asia, multinational companies such as Merck (US) established its Asia R&D headquarters in Wangjing Park, one of Beijing's rapidly expanding science and technology parks in 2011. In Singapore, attractive government co-investments have encouraged companies like GSK and Lonza to build substantial production capabilities in the country. Likewise, the Taiwanese government has recognized the importance of supporting the biotechnology industry in recent years and has created new initiatives such as the National Development Fund under the Executive Yuan. These efforts have prompted companies including Progen Pharmaceuticals (Australia) to tie up with local manufacturers such as Medigen Biotechnology Corp for their R&D activities to develop the PI-88 anti-cancer drug.
The shift in R&D investments is attributed to favourable government policies and regulations in Asian countries that collectively create an environment conducive for innovation. However, not all countries are as appealing when it comes to R&D spending. Within the APAC region, R&D investments appear to be moving from traditional to emerging R&D hotspots, with Australia standing out as an example of a conventional market struggling to retain R&D investments in the past few years.
Many APAC markets are competing as viable alternatives for cost-effective R&D and providing attractive commercialization opportunities. Countries that do not have the comfort of a large market size like China will need to enhance areas within their control, such as regulatory and tax environments, in order to continue drawing in funds for R&D.

Asia: An Emerging R&D Hub

Innovation in any industry, let alone healthcare, is improbable without investments in R&D. A minimum threshold of R&D is expected to drive healthy innovation across companies, countries, and regions. Not only does R&D investment fuel the development and growth of new products and technologies, but it also sparks curiosity, enthusiasm, and essential characteristics for a progressive and productive workforce. R&D expenditure is considered to be an essential criterion that reflects national development. It is influenced by a number of factors including political climate, fiscal policies, resource availability, and regulatory regimes.

Globally, there has been a decline in R&D spending, including in the healthcare industry. Even though healthcare has been more resilient on this front when compared with other industries, this trend is expected to reverse with the growing need for improvements in cost and quality of care across almost all countries and regions in the next few years. Between 2007 and 2012, total investment in healthcare R&D increased at a compound annual growth rate (CAGR) of only x %. The significant drop in global healthcare R&D spending in 2009 was a result of the recession as well as cuts in healthcare expenditure across developed markets, as a part of austerity measures.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Biobanks Global Market Opportunities And Strategies To 2023

Biobanks Global Market Opportunities And Strategies To 2023

  • $ 4000
  • March 2019

Biobanks Global Market Opportunities And Strategies To 2023 report provides the strategists, marketers and senior management with the critical information they need to assess the global biobanks market.Description: ...

Myocardial Infarction - Pipeline Review, H1 2019

Myocardial Infarction - Pipeline Review, H1 2019

  • $ 2000
  • March 2019

Myocardial Infarction - Pipeline Review, H1 2019SummaryGlobal Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Myocardial Infarction - Pipeline Review, H1 2019, provides an ...

Scientific Research And Development Services Global Market Report 2019

Scientific Research And Development Services Global Market Report 2019

  • $ 4000
  • January 2019

Scientific Research And Development Services Market Global Report 2019 provides the strategists, marketers and senior management with the critical information they need to assess the global scientific ...


Reportlinker.com © Copyright 2019. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on